$17.00
Manufacturer: Spain
Avertid (betahistine) solution is used to treat Meniere’s disease and syndrome, which are characterized by dizziness, hearing loss, and tinnitus.
Description
Ingredients
active ingredient: betahistine;
1 ml of the drug contains betahistine dihydrochloride 8 mg;
excipients : sodium saccharin, methylparaben (E 218), propylparaben (E 216), ethanol 96%, fruit flavor, purified water.
Does not contain sugar and dyes.
Dosage form
Solution for oral administration.
Basic physical and chemical properties: a clear, colorless liquid with a specific odor, a yellowish tint is allowed.
Pharmacotherapeutic group
Means used for vestibular disorders. ATX code N07C A01.
Pharmacodynamics
The mechanism of action of betahistine is to act on histamine H1 and H3 receptors of the labyrinth and vestibular nuclei of the central nervous system (CNS). Showing a pronounced H1-agonistic effect on the receptors of the vessels of the inner ear, the drug promotes local vasodilation and significantly improves blood circulation in the stria vascularis. The H3-antagonistic effect of the drug on the receptors of neurons of the vestibular nuclei improves microcirculation, capillary permeability, increases the release of histamine and increases fluid exchange at the level of the microcirculatory bed of the vascular band, which leads to normalization of endolymph pressure in the labyrinth and cochlea. In addition, betahistine improves the processes of neuronal transmission by increasing the concentration of serotonin in the synapses.
The drug is also an inhibitor of the enzyme diamine oxidase, which inactivates histamine. The binding of betahistine to voltage-dependent calcium channels of nerve cells, which are directly involved in the processes of ischemic damage, was also noted. The drug does not affect the H2-histamine receptors of the stomach and does not increase the secretion and concentration of hydrochloric acid, both basal and stimulated. Betahistine does not have a sedative effect, nor does it affect systemic blood pressure. Unlike other drugs in this group (cinnarizine, flunarizine), betahistine does not cause extrapyramidal disorders and can be used in elderly patients with Parkinson’s syndrome.
Indications
Meniere’s disease and syndrome, which are characterized by three main symptoms:
- dizziness, sometimes accompanied by nausea and vomiting;
- hearing loss (hard of hearing)
- tinnitus.
Symptomatic treatment of vestibular vertigo.
Contraindications
Hypersensitivity to the components of the drug, pheochromocytoma; treatment with disulfiram derivatives (Avertid contains 5% by volume of ethyl alcohol).
Dosage and administration
Adults take Avertide orally 2-3 times a day, preferably during or after a meal. The exact dosage of the drug is carried out using a syringe enclosed in the package. It is allowed to use an undiluted solution with a small amount of liquid, as well as dilute the drug in a small amount of liquid. Reduction of symptoms is sometimes observed only after 2-3 weeks of treatment. The best results are achieved when taking the drug for several months.
Usually the drug should be used at 8 mg (1 ml) 3 times a day. In case of severe symptoms of the disease or treatment failure, the dose can be increased to 16 mg (2 ml) 3 times a day or the drug can be used at 24 mg (3 ml) 2 times a day. The maximum daily dose is 48 mg.
Impaired liver and kidney function.
In this group of patients, special clinical trials of efficacy and safety have not been performed, but in accordance with experience after registration use, dose adjustment is not required.
Elderly patients. Although clinical trial data are currently limited in this group of patients, extensive experience with the drug in the post-registration period suggests that dose adjustment is not needed for this patient population.
Recent Reviews